Serveur d'exploration Tocilizumab - Analysis (France)

Index « Auteurs » - entrée « Tristan Pascart »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Tristan Bourcier < Tristan Pascart < Troels Herlin  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 2.
Ident.Authors (with country if any)Title
000289 (2017) Marie Desplats [France] ; Tristan Pascart [France] ; Germain Jelin [France] ; Laurène Norberciak [France] ; Peggy Philippe [France] ; Eric Houvenagel [France] ; Vincent Goeb [France] ; René-Marc Flipo [France]Are abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration? A questionnaire-based study.
000363 (2016) Tristan Pascart [France, Niger] ; Peggy Philippe [France] ; Elodie Drumez [France] ; Xavier Deprez [France] ; Bernard Cortet [France] ; Alain Duhamel [France] ; Eric Houvenagel [France] ; René-Marc Flipo [France]Comparative efficacy of tocilizumab, abatacept and rituximab after non‐TNF inhibitor failure: results from a multicentre study

List of associated KwdEn.i

Nombre de
documents
Descripteur
2Aged
2Arthritis, Rheumatoid (drug therapy)
2Female
2Humans
2Male
2Middle Aged
1Abatacept (administration & dosage)
1Abatacept (adverse effects)
1Abatacept (therapeutic use)
1Antibodies, Monoclonal, Humanized (administration & dosage)
1Antibodies, Monoclonal, Humanized (adverse effects)
1Antibodies, Monoclonal, Humanized (therapeutic use)
1Antirheumatic Agents (administration & dosage)
1Antirheumatic Agents (adverse effects)
1Antirheumatic Agents (therapeutic use)
1Arthritis, Rheumatoid (blood)
1Arthritis, Rheumatoid (diagnosis)
1Arthritis, Rheumatoid (immunology)
1Biological Products (adverse effects)
1Biological Products (therapeutic use)
1Biomarkers (blood)
1Blood Sedimentation
1C-Reactive Protein (metabolism)
1Cross-Sectional Studies
1Drug Substitution
1France
1Infusions, Intravenous
1Injections, Subcutaneous
1Patient Preference (statistics & numerical data)
1Retrospective Studies
1Rituximab (adverse effects)
1Rituximab (therapeutic use)
1Severity of Illness Index
1Surveys and Questionnaires
1Time Factors
1Treatment Failure

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/France/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/Author.i -k "Tristan Pascart" 
HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/Author.i  \
                -Sk "Tristan Pascart" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/France/Analysis/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    France
   |étape=   Analysis
   |type=    indexItem
   |index=    Author.i
   |clé=    Tristan Pascart
}}

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021